IFNA17 and chronic hepatitis: In chronic hepatitis C virus (HCV) infection, it has previously been shown that patients with strong ISG‐signatures have a lower chance of responding to treatment with IFNα, clearly demonstrating the in vivo relevance of interferon pathway desensitization (Chen et al, 2005).